In the ever-growing field of life sciences, it is important to always be learning. As frequent authors of industry-respected whitepapers and presenters at biopharma conventions, the practices of EVERSANA  CONSULTING are always working to stay at the forefront of this evolving field. Read some of our recent insights, case studies and other resources below.

Here Are the Latest Insights Across Practices

Early involvement of Medical Affairs in the product lifecycle is not just beneficial – it is mission critical. In the swiftly changing realm of advanced therapies like biosimilars, rare disease molecules, and cell and gene therapies, a strong scientific interpretation and orientation is essential. Medical Affairs teams are stepping up to this challenge, actively shaping […]

In the dynamic landscape of healthcare and life sciences, the integration of cutting-edge technologies has become paramount. Among these innovations, Artificial Intelligence (AI) stands out as a transformative force, reshaping everything from drug discovery to patient care. In this white paper, Tanuj Mehra, Jordan Schell, Erion Lipo and Kevin Yin shed light on the pivotal […]

Introduction At EVERSANA, we’re at the forefront of regulatory work in Canada, and recently, our team has been delving into the realm of PRCI (Public Release of Clinical Information) in  Canada and submission Policy 0070 (Regulation EMA (EU) 536/2014) in Europe). In a recent conversation, Deborah Brown, Lead, Strategic Partnerships, sheds light on the intricacies […]

Discover how EVERSANA’s cutting-edge approach is revolutionizing patient identification for cell and gene therapies. In our white paper, “Lead Time Is All You Need: Patient Identification for Cell and Gene Therapies Using Machine Learning and Advanced Data Analytics,” we explore the transformative power of machine learning and advanced data analytics in the world of healthcare. […]

Discover the groundbreaking strategy that could redefine pharmaceutical launches and propel your product’s success across North America. In the realm of pharmaceutical launches, a paradigm shift is underway, challenging the conventional sequential approach and calling for a bolder strategy that reaps unparalleled benefits. “Unlocking Your Full North American Potential: Coordinating Launches in The U.S. and […]

The pharmaceutical industry faces a host of increasingly complex challenges and critical decisions when attempting to manage and predict their products’ plausible revenue patterns. The mishandling of revenue forecasting and evaluation can result in substantial financial liabilities, which has become more of an issue for manufacturers as products, disease states and additional factors that previously […]

Pharmaceutical manufacturers commonly invest a considerable amount of time, money and additional resources into revenue management. Most would likely say they desire to invest even more because of the significant impact it has on their products’ gross-to-net. But how and where to invest valuable assets is a significant decision. The process of revenue management, including […]

Pharmaceutical manufacturers specializing in Rare Disease, Oncology, Personalized Cancer Immunotherapy, and Cell and Gene therapies encounter a range of complex challenges, including advancements in medicine and technology, changing patient and provider needs, market access, regulatory pathways, pricing transparency, patient reach, patient adherence, and ever evolving disease states. Despite spending over $200 million on product launches, […]

These are just some of the trends currently shaping the Canadian market access environment. Achieving favourable market access and reimbursement outcomes for new treatments in this ever-changing landscape requires intimate knowledge of the Canadian landscape, processes and key stakeholders, careful strategic planning, sound tactics and skilled execution. Some key steps and considerations to maximize the […]

The various complexities and ever-changing nature of the pharmaceutical and health care industries create endless intricate processes, datasets and other components for manufacturers to navigate. Properly maintaining a Customer Master can be one of the most challenging and time-consuming undertakings that, depending how efficiently and successfully it is carried out, can either extensively benefit or […]

In-licensing is a significant growth lever for a variety of reasons, including: Serving as a risk mitigation tool Reinforce a company’s therapeutic area footprint Serving as a growth catalyst channel to further diversify your pipeline and product portfolio. A Once-in-a-Lifetime Moment of Market Conditions The opportunity at hand for large pharma has been created by […]

The cell therapy market continues to grow. Estimated at $101 billion in 2021, the global cell therapy market is projected to reach $247 billion by 2028, a CAGR of 13.64%.1  The revenue generation is being driven by technological advancements in manufacturing processes and developments in CAR T-cell therapy for solid tumors, and the approvals and […]

Need advisors focused exclusively on the life sciences industry?

We can help you address strategic, tactical and operational concerns to increase value across your entire product lifecycle.